Impact Investing Solutions Announces the Legacy of Impact and Love Retreat to Discover Life's Purpose
Impact Investing Solutions launches an exclusive retreat in Switzerland in Q4, an invitation-only event for self-discovery, allowing investors to realize their true legacy and love within.
Zug, Switzerland, May 27, 2025 (GLOBE NEWSWIRE) -- This November, a rare and transformative event by Impact Investing Solutions (IIS) and BE SHIRO Foundation, is unfolding in the serene Swiss countryside, a private, weeklong 'Legacy of Impact and Love' retreat designed specifically for seasoned investors ready to shift their capital and consciousness toward global impact. Limited to just 15 carefully selected participants, this immersive experience will take place at Kloster Fischingen, a historic monastery near the forest, from 22nd to 29th November 2025. It will offer the perfect backdrop for profound inner work and deeper personal realignment.
Legacy of Impact and LoveBehind this initiative is a forward-thinking organization with a mission to accelerate the flow of capital into meaningful, world-changing causes. Drawing from ancient meditative practices, cutting-edge AI matchmaking, and years of experience in impact investing, the retreat will help participants align their resources with their deepest values, what the organizers call going beyond impact.
Why this event? Because too many successful individuals, despite their financial achievements, still feel something is missing.
'Money doesn't make you whole,' says Sveta Banerjee, founder and CEO of IIS. 'You can have all the earthly possessions and still find yourself looking up at the stars, hoping for more. But when you look inward and realize what you truly want to bring to this world, that is what brings true fulfillment."
This retreat is for those who have built wealth and influence but are seeking a more authentic legacy. Attendees will work closely with a handpicked team of four facilitators, including Sveta, the co-founder Ben Banerjee, alongside Andreas Dudas and Antoinette Haering of BE SHIRO, a Swiss-based cluster dedicated to empowering individuals to turn their unique life purpose into impactful change. Together, they'll guide participants through soul-centered meditations, purpose discovery, and deep conversations about how to activate philanthropic or impact capital in alignment with their true selves.
The retreat's exclusivity is deliberate. With only 15 spots available, the experience is highly personalized to ensure every participant has the space, time, and guidance to go inward and connect deeply with what truly matters.
Using refined AI matchmaking systems and insights gathered from years of working at the intersection of wealth, purpose, and social change, the team behind this initiative believes now is the time. 'We're seeing more and more investors holding back capital, not because they don't want to make a difference, but because they're still trying to decide with their heads,' says Sveta. 'This retreat helps them decide with their hearts.'
The idea behind this retreat is truly for participants to uncover their life's true mission and then channel their wealth, whether through investments or philanthropy, into causes that ignite that mission. That's how real change happens. That's how legacies are built. With a powerful team, ancient teaching, and an extraordinary setting, this retreat offers something truly unique: a bridge between wealth and purpose, between success and fulfillment.
With the retreat taking place this November and demand already building, now is the time to apply. By securing their place, individuals can solidify their place in global impact.
Media Contact:
Name: Legacy of Impact and Love Retreat Team
Email: apply@iisolutions.ch
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Crypto kidnapping victim's dizzying view during alleged weeks-long torture ordeal
This is likely the dizzying view forced on crypto kidnapping victim Michael Valentino Teofrasto Carturan when he was allegedly dangled over a five-story staircase while being tortured for his Bitcoin password. Real estate photos of the eight-bedroom $21 million-dollar townhouse on Prince Street in SoHo where authorities said Carturan, 28, was abused and held captive for 17 days show the spiral, multi-level plunge he is believed to have faced during the harrowing ordeal. The native of Italy, who is worth $30 million, suffered serious injuries in the horrific episode, during which Manhattan prosecutors alleged he was tied to a chair with electrical wire, tased while standing in water, cut on his legs and arm with a chainsaw, urinated on and forced to take drugs. His accused tormentors — crypto entrepreneur John Woeltz and Swiss business man William Duplessie — also allegedly destroyed Carturan's passport. Carturan was rescued after he fled the townhouse barefoot on May 23 and flagged down a traffic cop for help. The former captive has already contacted the Italian consulate on the Upper East Side in order to get a new passport, Italian newspaper La Repubblica reported. 'Only on Saturday did the first contacts take place between the family (who said little or nothing keeping the conditions and the account of what happened confidential) and the Italian Foreign Ministry,' according to the outlet. His family owns a herbalist shop, according to the Italian newspaper Corriere della Sera. Carturan was living in Rivoli, a town in the city of Turin in northern Italy, with his family before venturing to the Big Apple on May 6 to meet Woeltz, according to authorities and sources. He had studied psychology before dropping out of school to trade crypto, the Italian press reported. He was apparently hoping to retrieve Bitcoin allegedly stolen from him by Woeltz and Duplessie, who then turned the tables, took him captive and threatened to kill him and his family unless he gave them the password to his bitcoin wallet, prosecutors said. Woeltz, 37, of Kentucky, is believed to be worth $100 million. Polaroids that were found at the property showed Carturan — who reportedly has a net worth of $30 million — with a gun pointed at his head and being forced to smoke crack cocaine, authorities said. The pair are due in court June 11.
Yahoo
2 hours ago
- Yahoo
Fast-casual stir-fry chain looking to make central Ohio debut in Gahanna
GAHANNA, Ohio (WCMH) – A fast-casual stir-fry chain may open its first central Ohio location near Gahanna. Honeygrow has applied for a permit to renovate 4782 Morse Road, according to Columbus city documents. A spokesperson said the brand is currently in the midst of lease negotiations for the space. The building formerly housed Mod Pizza, which closed last year amid financial troubles for the chain. Honeygrow has three Ohio eateries, located in Canton, Akron and Strongsville. Founded in 2012, the Pennsylvania-based chain has around 40 locations across the northeastern portion of the United States, according to its website. The business serves a variety of Asian-inspired stir fries, featuring noodles, meat, vegetables and sauce. The eatery also serves salads and desserts, such as fruit cups with sweet toppings called 'honeybars' and brownies. Customers have the option to build their own stir fry bowls, honeybars and salads. Honeygrow offers dine-in and take out at its restaurants, along with catering services. The company said it can not share any further information about the potential Gahanna location at this time. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
2 hours ago
- Yahoo
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
Data Highlights Transformative Promise of CAR T in Solid Tumors Phase 1 Trial with ALLO-316 Demonstrated Potential to Provide Meaningful Clinical Benefit in Patients with CD70 TPS ≥ 50% Advanced or Metastatic RCC A Single Dose of ALLO-316 Achieved a 31% Confirmed Response Rate Four of Five Confirmed Responders Remain in Response Including One Ongoing Remission Over 12 Months Robust Expansion, Persistence, and Tumor Infiltration of ALLO-316 Seen with Standard Lymphodepletion, Showcasing Dagger® Technology as a Next-Generation Allogeneic Platform Phase 1 Safety Profile was Manageable; Proactive Diagnostic and Management Strategies Proved Effective in Mitigating IEC-HS While Preserving Efficacy SOUTH SAN FRANCISCO, Calif., June 01, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, presented updated data from the Phase 1 TRAVERSE study of ALLO-316 in renal cell carcinoma (RCC) during an oral presentation at the 2025 ASCO Annual Meeting. The Phase 1 TRAVERSE trial enrolled patients with advanced or metastatic renal cell RCC. Leveraging the proprietary Dagger® technology to enable robust CAR T cell expansion, it stands as the first and only allogeneic CAR T product to show promise in treating solid tumors. The presentation focused on the Phase 1b expansion cohort from the Phase 1 TRAVERSE study in which patients were treated with a standard regimen of cyclophosphamide and fludarabine followed by a single dose of 80 million AlloCAR T™ cells. 'ALLO-316 is showing clear evidence of targeted antitumor activity in patients who had failed most or all approved therapies for advanced or metastatic renal cell carcinoma,' said Zachary Roberts, M.D., Ph.D., EVP, Research and Development and Chief Medical Officer at Allogene. 'Our proprietary Dagger technology allows the use of a standard cyclophosphamide and fludarabine-based lymphodepletion regimen with a single dose of ALLO-316. Strong CAR T-cell kinetics and extensive infiltration of tumor tissue by CAR T cells are combining to generate deep and durable remissions. These are results that were previously considered out of reach for patients with advanced solid tumors.' 'Patients diagnosed with advanced or metastatic renal cell carcinoma often face a median survival in months after exhausting standard therapies,' said Samer A. Srour, MB ChB, MS, Associate Professor of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center and lead investigator of the TRAVERSE trial. 'These updated results from a larger cohort of patients with confirmed CD70 positive tumors provide compelling evidence that treatment with ALLO-316 can reduce tumor burden, control disease, and in some cases deliver durable responses. These findings underscore the clinical promise of an allogeneic CAR T to address the significant unmet needs in solid tumors and offer hope to patients who have exhausted other options.' In the Phase 1b expansion cohort, 22 patients whose tumors had progressed on multiple prior therapies were treated with lymphodepletion and 20 were treated with ALLO-316. All patients had tumors resistant to immune checkpoint blockers and at least one tyrosine kinase inhibitor (TKI), 82% had ≥2+ prior TKI, and 41% had prior belzutifan. Sixteen of the ALLO-316 treated patients had a high CD70 Tumor Proportion Score (TPS >50%). The Phase 1b expansion cohort evaluated the safety and efficacy of ALLO-316 at DL2 (80M CAR T cells) following a standard FC lymphodepletion regimen (fludarabine (30 mg/m2/day) and cyclophosphamide (500 mg/m2/day) for 3 days). The median time from enrollment to the start of therapy was four days. A single dose of ALLO-316 stabilized or reversed disease progression in the majority of patients. In the 16 patients with CD70 TPS ≥50%, the trial demonstrated a Confirmed Overall Response Rate (ORR) of 31% with 44% achieving a minimum of 30% reduction in tumor burden. Of the five confirmed responders, four maintain ongoing responses, with one in sustained remission for over 12 months. The median duration of response (mDOR) has not yet been reached, indicating the potential for long-term disease control. CD70+ patients Phase 1b(N=20) ORR (confirmed CR or PR per RECIST v1.1), n/N (%) 5/20 (25) CD70 TPS ≥50%CD70 TPS <50% 5/16 (31)0/4 (0) RECIST v1.1, Response Evaluation Criteria in Solid Tumors, version 1.1; TPS, tumor proportion score The safety profile of ALLO-316 was manageable and consistent with lymphodepletion and an active CAR T product. The most frequent Grade ≥3 events were hematologic and there were no treatment-related Grade 5 events. The most common all-grade adverse events were cytokine release syndrome (CRS) (68%; with no grade ≥3), neutropenia (68%), decreased white blood cell count (68%), anemia (59%), and thrombocytopenia (55%). Immune effector cell-associated neurotoxicity syndrome (ICANS) was 18% (with no grade ≥3) and no graft-versus-host disease (GvHD) occurred. Improved recognition of IEC-HS symptoms led to diagnosis in 36% of patients with 2 patients (9%) experiencing a short-term Grade 3 (one) or Grade 4 (one patient) event. Newly implemented diagnostic and management algorithms significantly mitigated IEC-HS, with no associated Grade 5 events. TEAEs ≥20% incidence in Phase 1b, n (%) Phase 1b (N=22a) All Grades Grade ≥3 Neutropenia 15 (68) 15 (68) White blood cell count decreased 15 (68) 15 (68) Anemia 13 (59) 9 (41) Thrombocytopenia 12 (55) 6 (27) Nausea 8 (36) 0 ALT increased 7 (32) 2 (9) Peripheral edema 7 (32) 0 Pyrexia 7 (32) 0 Arthralgia 6 (27) 0 AST increased 6 (27) 2 (9) Fatigue 5 (23) 0 Headache 5 (23) 0 AEs of Special Interest Any Grade Grade ≥3 CRS 15 (68) 0 Infection 10 (45) 8 (36) IEC-HS 8 (36) 2 (9)b ICANS 4 (18) 0 Graft-versus-host disease 0 0 IEC-HS includes the preferred terms immune effector cell-associated HLH-like syndrome and Hemophagocytic lymphohistiocytosis. a Includes 2 patients who received LD but did not receive ALLO-316 b One patient experienced G4 IEC-HS based on GI bleeding with subsequent improvement and 1 patient experienced G3 IEC-HS based on hypotension managed without pressors with subsequent improvement. About ALLO-316 (TRAVERSE)ALLO-316 is an AlloCAR T™ investigational product targeting CD70, which is highly expressed in renal cell carcinoma (RCC). CD70 is also selectively expressed in several cancers, creating the potential for ALLO-316 to be developed across a variety of both hematologic malignancies and solid tumors. The ongoing Phase 1 TRAVERSE trial is designed to evaluate the safety, tolerability, and activity of ALLO-316 in patients with advanced or metastatic clear cell RCC. In October 2024 the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation based on the potential of ALLO-316 to address the unmet need for patients with advanced or metastatic RCC. The FDA previously granted Fast Track Designation (FTD) to ALLO-316 in March 2023. In April 2024, the Company announced an award from the California Institute for Regenerative Medicine (CIRM) to support the ongoing TRAVERSE trial with ALLO-316 in RCC. About Allogene TherapeuticsAllogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of 'off-the-shelf' CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit and follow @AllogeneTx on X and LinkedIn. Cautionary Note on Forward-Looking Statements for Allogene This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release may, in some cases, use terms such as 'develop,' 'potential,' 'expect,' 'can,' 'enable,' 'showing,' 'generate,' 'may,' 'could,' 'designed to,' 'promise,' 'hope,' 'ongoing,' 'indicating,' 'mitigate,' 'evaluate,' 'pioneer,' 'goal' or 'will,' including alternative forms thereof, or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the potential of ALLO-316 to treat patients with advanced or metastatic RCC or to provide meaningful clinical benefit in patients with advanced RCC; the potential for ALLO-316 to be developed across a variety of both hematologic malignancies and solid tumors and to generate deep and durable remissions; the potential that ALLO-316 can reduce tumor burden, control disease, and deliver durable responses; the design and potential benefits of our Dagger technology; whether the Dagger® technology will become the next-generation allogeneic platform; ALLO-316 and the Dagger technology's ability to enable robust CAR T cell expansion and persistence and tumor infiltration; the potential of ALLO-316 to address the unmet need in solid tumors or offer hope to patients who have exhausted other options; the transformative potential of our AlloCAR T™ in solid tumors; the potential advantages of the RMAT and Fast Track designation; and our ability to deliver cell therapy on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene's expectations and actual results, including, risks and uncertainties related to: the limited nature of our Phase 1 data from our clinical trials and the extent to which such data may or may not be validated in any future clinical trials; the extent to which the Food and Drug Administration disagrees with our clinical or regulatory plans or the import of our clinical results, which could cause future delays to our clinical trials or require additional clinical trials; we may encounter difficulties enrolling patients in our clinical trials; we may not be able to demonstrate the safety and efficacy of our product candidates in our clinical trials, which could prevent or delay regulatory approval and commercialization; RMAT and Fast Track designations may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval and the designations can be revoked if the criteria for eligibility cease to be met; and challenges with manufacturing or optimizing manufacturing of our product candidates. These and other risks are discussed in greater detail in Allogene's filings with the Securities and Exchange Commission (SEC), including without limitation under the 'Risk Factors' heading in its Quarterly Report on Form 10-Q for the year ended March 31, 2025. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. AlloCAR T™ and Dagger® are trademarks of Allogene Therapeutics, Inc. Allogene's investigational AlloCAR T™ oncology products utilize Cellectis technologies. The anti-CD70 AlloCAR T program is licensed exclusively from Cellectis by Allogene and Allogene holds global development and commercial rights to this AlloCAR T™ program. Allogene Media/Investor Contact:Christine CassianoEVP, Chief Corporate Affairs & Brand Strategy while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
